Sarasin & Partners’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
Other funds holding NBIX
Sarasin & Partners's NBIX Position: Q3 2026 in Review
Sarasin & Partners opened a new position in Neurocrine Biosciences (NBIX) in Q3 2026: 15,100 shares worth $2.14M. The stake represents 0.02% of the portfolio and ranks #88 among its holdings.
771 funds tracked by Wall St. Rank hold NBIX as of Q3 2026.
- Sarasin & Partners held 15,100 shares of Neurocrine Biosciences worth $2.14M as of Q3 2026.
- Neurocrine Biosciences was a new Sarasin & Partners position in Q3 2026.
- Neurocrine Biosciences made up 0.02% of Sarasin & Partners's portfolio in Q3 2026, its #88 holding.
- 771 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2026.
Based on Sarasin & Partners's 13F filing for Q3 2026, filed 13 Oct 2026.